Skip to content

Feasibility and application of trimetazidine in 18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients

Feasibility and application of trimetazidine in 18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038559
Enrollment
Unknown
Registered
2020-09-24
Start date
2017-09-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic mellitus, coronary artery disease

Interventions

Gold Standard:18F-FDG PET myocardial glucose metabolism imaging after glucose loading / insulin injection was used as the reference standard.
imaging&#32
after&#32
trimetazidine&#32
combined&#32
with&#32
loading&#32
injection

Sponsors

The Third Affiliated Hospital of Suzhou University / Changzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with myocardial infarction or ischemic cardiomyopathy complicated with diabetes; (2) Left ventricular ejection fraction <45%; (3) Patients who were used rest myocardial perfusion imaging (MPI) combined with PET gated myocardial metabolic imaging (MMI) to assess viable myocardium.

Exclusion criteria

Exclusion criteria: (1) Patients with acute myocardial infarction or unstable angina occurred within past one month; (2) Severe arrhythmia; (3) Normal rest MPI; (4) Dilated cardiomyopathy or hypertrophic cardiomyopathy; (5) Serious liver, kidney, respiratory system and blood system diseases; (6) Pregnant women, lactating women or women of childbearing age who have fertility requirements; (7) There were other situations in which the researchers considered that it was not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Myocardial glucose metabolism;

Countries

China

Contacts

Public ContactYuetao Wang

The Third Affiliated Hospital of Suzhou University / Changzhou First People's Hospital

yuetao-w@163.com+86 13852040196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026